Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP + HepB + IPV vaccine
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP + HepB + IPV vaccine is a **combination vaccine** that provides immunization against **diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and poliovirus** (types 1, 2, and 3). It contains **diphtheria toxoid**, **tetanus toxoid**, **acellular pertussis antigens** (inactivated pertussis toxin, filamentous hemagglutinin, pertactin, fimbriae types 2 and 3), **hepatitis B surface antigen**, and **inactivated poliovirus**. The vaccine acts by eliciting an immune response against the bacteria and viruses responsible for these serious diseases, stimulating the production of protective antibodies. It is used as part of the routine pediatric vaccination series to confer immunity early in life and reduce the morbidity and mortality associated with these infections[3][7].
- Brand names
- Vaxelis
- Other names
- DTaP-HepB-IPV vaccineDTaP + HepB + IPV vaccine
02
Targets
PRN (Pertactin)HBsAg (Hepatitis B surface antigen)FIM2/FIM3 (Fimbriae types 2 and 3)Diphtheria toxin
Beyond the preview
Go deeper on DTaP + HepB + IPV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP + HepB + IPV vaccine.